Renal function and eGFR strata in antibiotic PK/PD
Many antibiotics leave the body through the kidney. When clearance depends on renal function, two patients on the “same” regimen can live in different exposure worlds. One has high free levels and long time above MIC. Another clears the drug so fast the troughs collapse.
That is why serious virtual populations often stratify by eGFR or similar kidney metrics instead of pretending one clearance distribution fits everybody.
Modeling structure for renally cleared drugs. Not individualized clinical dosing advice.
Why kidney function changes the plot
If clearance rises as eGFR rises, the concentration-time curve sits lower for better renal function, all else equal. For time-driven targets, that can erase trough coverage first. For continuous infusion, steady free concentration moves almost directly with clearance. For AUC-driven targets, the whole area shrinks.
So renal strata are not decorative subgroups. They are different pharmacokinetic machines.
Better kidney function can mean less exposure on the same nominal regimen.
Augmented renal clearance
Some critically ill patients clear drugs unusually fast. If your virtual population never includes that tail, PTA for “ICU adults” can look calmer than the ward you claim to study.Building strata without clutter
A practical pattern:
- Define eGFR classes that match the covariate model you cite.
- Draw subjects inside each class, or draw eGFR then map to clearance.
- Report PTA within strata and overall.
- Keep dosing rules explicit if the labeled regimen itself adjusts by kidney function.
If the clinical regimen reduces dose in low eGFR, your simulation should not compare “full dose in everyone” unless that is the deliberate what-if.
Useful for understanding raw pharmacokinetic sensitivity to kidney function. Can overstate exposure in low eGFR and understate risk in high eGFR relative to labeled practice.
Closer to practice questions. Each stratum gets its regimen rule, then PTA is compared under those rules. Still cite which adjustment scheme you implemented.
What to report so readers can trust you
Name the equation used for renal function, the class boundaries, the clearance relationship, and whether dialysis or renal replacement scenarios were excluded. Mixed populations without labels are hard to reuse and easy to over-interpret.
What changes in the figure when you stratify
Overall PTA can hide a split world: strong attainment in low eGFR and fragile attainment in high eGFR on the same nominal dose. Or the reverse after renal dose reductions that overshoot. Stratified plots make that visible. A single pooled PTA can average the tension away.
When you present, show at least one stratum contrast beside the overall number. Readers who treat ICU kidneys as one bin will misuse your result. Readers who see the bins can argue with you productively about class boundaries and clearance equations.
If renal replacement therapy is excluded, say that in the first methods paragraph. Mixed RRT and non-RRT evidence is a classic provenance trap.
Also write down which equation produced eGFR or creatinine clearance in your covariate chain. Switching formulas mid-project is a quiet way to invent a new population without noticing.
If body size and renal function both enter clearance, keep that structure intact in the virtual draws. Dropping weight while keeping eGFR, or the reverse, can warp the tails that decide PTA at higher MIC values.
Takeaway
For renally cleared antibiotics, eGFR is not a demographic decoration. It reshapes clearance, exposure geometry, and attainment. Put kidney function into the virtual population on purpose, then say whether dosing was fixed or adjusted.
Previous: Effect site versus plasma · Next: Inoculum effect.